explore -WSS

explore

author：entertainment 2025-08-31 21:01:16 - browse：47387

Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed reductions in bad cholesterol levels — study results that are preliminary but signal the potential for gene-editing treatments to benefit people with an inherited type of cardiovascular disease.

Three of the study participants treated with potentially therapeutic doses of the Verve drug, called VERVE-101, showed reductions in LDL-C levels of 39%, 48%, and 55%, respectively. The latter patient’s decline in so-called “bad” cholesterol was maintained for six months.

The Verve-101 study results were presented at the American Heart Association conference and are the first data in patients from a therapy that uses base editing to change individual letters of DNA. Verve licensed the base-editing technology from Beam Therapeutics.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Anger, defiance, fear over Supreme Court decision to block student loan forgiveness

leisure time

focus

WSS

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

Microbiome research is starting to find links to chronic diseases

ADA: All diabetes patients should be screened for liver condition

Tuskegee Airman Raymond Cassagnol dies at 102

CommonSpirit Health keeps growing, even as it loses money

Lasker Awards 2023: Winners in biomedical research

leisure time

explore

leisure time

Heart attack and stroke risk calculators need revising

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

Apple is now the first public company to be valued at $3 trillion

Experts study whether long Covid risk adds up with each reinfection

Hepatitis C has a cure — but many Americans still lack access to it

How AI helped researchers track recovery from depression

Psychedelics group wrestles with new pharma identity

It's been 20 years since Dolly the sheep. Where's my clone?

After affirmative action ruling, medical educators look to 'holistic review'

Microbiome research is starting to find links to chronic diseases

entertainment

Why do we get seasonal allergies?

Senators: Long

Intarcia’s device

Changes to biosimilar regulatory framework must prioritize patients

Why are Kaiser Permanente staff considering a strike?

Why are Kaiser Permanente staff considering a strike?

leisure time

hotspot

focus

explore